XIEMTI Trademark
Serial Number: 79225739
XIEMTI is a trademark filed by
PHARNEXT
on November 14, 2017. The trademark is classified under Class 5 (Pharmaceuticals).
The application is currently no longer active.
Trademark Classes
Owner Contact Info
Legal Representation
Trademark Details
Filing Date
November 14, 2017
Registration Date
Not Registered
Published for Opposition
July 10, 2018
Goods & Services
Medicines, pharmaceutical products, pharmaceutical preparations, medical preparations, and biological preparations for medical use, namely, all used for the treatment of neurodegenerative diseases
Filing History
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 22, 2019 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Nov 5, 2019 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 5, 2019 FICR
ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Nov 5, 2018 MAB5
ABANDONMENT - AFTER PUBLICATION
Nov 5, 2018 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Oct 31, 2018 EXAR
EXTENSION OF TIME TO OPPOSE RECEIVED
Aug 9, 2018 ETOF
NOTIFICATION PROCESSED BY IB
Jul 21, 2018 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 10, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jul 10, 2018 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 4, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 4, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 20, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 6, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 6, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 6, 2018 TROA
REFUSAL PROCESSED BY IB
Mar 16, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 27, 2018 RFCS
REFUSAL PROCESSED BY MPU
Feb 27, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 20, 2018 RFCR
NON-FINAL ACTION WRITTEN
Feb 19, 2018 CNRT
ASSIGNED TO EXAMINER
Feb 13, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 9, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 5, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 1, 2018 REPR